HEC Forum 27 (4):417-429 (2015)

Abstract
Plasma protein therapies are a group of essential medicines extracted from human plasma through processes of industrial scale fractionation. They are used primarily to treat a number of rare, chronic disorders ensuing from inherited or acquired deficiencies of a number of physiologically essential proteins. These disorders include hemophilia A and B, different immunodeficiencies and alpha 1-antitrypsin deficiency. In addition, acute blood loss, burns and sepsis are treated by PPTs. Hence, a population of vulnerable and very sick individuals is dependent on these products. In addition, the continued well-being of large sections of the community, including pregnant women and their children, travelers and workers exposed to infectious risk is also subject to the availability of these therapies. Their manufacture to adequate amounts requires large volumes of human plasma as the starting material of a complex purification process. Mainstream blood transfusion services run primarily by the not-for-profit sector have attempted to provide this plasma through the separation of blood donations, but have failed to provide sufficient amounts to meet the clinical demand. The collection of plasma from donors willing to commit to the process of plasmapheresis, which is not only time consuming but requires a long term, continuing commitment, generates much higher amounts of plasma and has been an activity historically separate from the blood transfusion sector and run by commercial companies. These companies now supply two-thirds of the growing global need for these therapies, while the mainstream government-run blood sector continues to supply a shrinking proportion. The private sector plasmapheresis activity which provides the bulk of treatment products has been compensating the donors in order to recognize the time and effort required. Recent activities have reignited the debate regarding the ethical and medical aspects of such compensation. In this work, we review the landscape; assess the contributions made by the compensated and non-compensated sectors and synthesize the outcomes on the relevant patient communities of perturbing the current paradigm of compensated plasma donation. We conclude that the current era of “Patient Centeredness” in health care demands the continuation and extension of paid plasma donation
Keywords Rare disorders  Ethics of donation  Volunteerism
Categories (categorize this paper)
ISBN(s)
DOI 10.1007/s10730-014-9253-5
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 53,548
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

Add more citations

Similar books and articles

`What Blood Told Dr Cohn': World War II, Plasma Fractionation, and the Growth of Human Blood Research.H. N. - 1999 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 30 (3):377-405.
`What Blood Told Dr Cohn': World War II, Plasma Fractionation, and the Growth of Human Blood Research.Angela N. H. Creager - 1999 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 30 (3):377-405.
Compensated Kidney Donation: An Ethical Review of the Iranian Model.Alireza Bagheri - 2006 - Kennedy Institute of Ethics Journal 16 (3):269-282.
Paying Organ Donors.J. Harvey - 1990 - Journal of Medical Ethics 16 (3):117-119.

Analytics

Added to PP index
2014-09-18

Total views
57 ( #166,875 of 2,348,315 )

Recent downloads (6 months)
4 ( #186,050 of 2,348,315 )

How can I increase my downloads?

Downloads

My notes